Search
Sitimagene ceradenovec
go.drugbank.com/drugs/DB04907ExperimentalSitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy
TST10088
go.drugbank.com/drugs/DB05151ExperimentalTST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by the matrix metalloproteinases which are known to be involved in tumor growth and metastasis
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigationalto its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor antagonist approved by the FDA. … Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative
Products: ENTYVIO PenMeningococcal polysaccharide vaccine group Y
go.drugbank.com/drugs/DB13888ApprovedInvestigational*N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. … It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.
Lumicitabine
go.drugbank.com/drugs/DB14808InvestigationalTablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations). … Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and
4-Phenylfentanyl
go.drugbank.com/drugs/DB09168ExperimentalIllicit4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted
Synonyms: N-(1-Phenethyl-4-phenyl-4-piperidyl)-N-phenyl-propanamideTalmapimod
go.drugbank.com/drugs/DB05412InvestigationalTalmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.